EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer

Taiju Ando, Yuko Oya, Yumi Tomiie, Kimio Ogawa, Tomoki Kuki, Yosuke Tanabe, Hisayuki Kato, Kazuyoshi Imaizumi, Yatsuka Hibi, Kenji Kawada

International Journal of Clinical Oncology · 2025-11 · 30 (11) · 2257-2265

DOI: 10.1007/s10147-025-02861-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 22.08.2025. Verfasst von Taiju Ando und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. 81023003@fujita-hu.ac.j…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

BRAF V600E mutation is a key oncogenic driver commonly found in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC). Dabrafenib plus trametinib combination therapy targeting this mutation has shown promising activity in clinical trials. This study aimed to verify the real-world effectiveness of this combination therapy in patients with BRAF V600E -positive PTC and ATC.

Methods

We retrospectively investigated adult patients with BRAF V600E -positive PTC and ATC who were treated with dabrafenib plus trametinib at a single university hospital in Japan.

Results

Between January 2024 and December 2024, 10 patients with PTC and 6 patients with ATC were identified, among whom 13 patients (81%) had been previously treated with lenvatinib. An objective response was observed in 5 patients with PTC (50%) and 4 patients with ATC (67%). The median progression-free survival and overall survival were not reached in patients with PTC, and were 2.7 months and 3.6 months, respectively, in patients with ATC. Partial regression of intracranial metastatic tumors was observed in 1 of the 2 patients with brain metastases at baseline. Rechallenge with another BRAF/MEK inhibitor combination therapy, encorafenib plus binimetinib, was attempted in 2 patients with ATC and demonstrated clinically meaningful responses.

Conclusions

Dabrafenib plus trametinib combination therapy demonstrated clinical effectiveness in patients with BRAF V600E -positive thyroid cancer, with response rates comparable to those observed in clinical trials. However, tumor shrinkage did not appear to translate into improved survival in patients with ATC, highlighting the limitations of current targeted therapies in managing this aggressive subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsThyroid NeoplasmsThyroid Carcinoma, AnaplasticThyroid Cancer, PapillaryHumansFemaleMaleRetrospective StudiesMiddle AgedOximesAgedPyridonesPyrimidinonesImidazolesMutationAdultProgression-Free Survival

Stichwörter der Autor:innen

BRAF V600EDabrafenibThyroid cancerTrametinib

Substanzen

dabrafenibtrametinibProto-Oncogene Proteins B-rafOximesPyridonesBRAF protein, humanPyrimidinonesImidazoles

Autor:innen und Institutionen

  • Department of Medical Oncology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. 81023003@fujita-hu.ac.jp.
  • Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan.
  • Department of Endocrine Surgery, Fujita Health University, Toyoake, Aichi, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, Fujita Health University, Toyoake, Aichi, Japan.
  • Department of Medical Oncology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Zitieren

APA

Ando, T., Oya, Y., Tomiie, Y., Ogawa, K., Kuki, T., Tanabe, Y., Kato, H., Imaizumi, K., Hibi, Y., & Kawada, K. (2025). A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer. International Journal of Clinical Oncology, 30(11), 2257-2265. https://doi.org/10.1007/s10147-025-02861-8

Vancouver

Ando T, Oya Y, Tomiie Y, Ogawa K, Kuki T, Tanabe Y, et al. A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer. International Journal of Clinical Oncology. 2025;30(11):2257-2265. doi:10.1007/s10147-025-02861-8

BibTeX
@article{Ando2025,
  author = {Ando, Taiju and Oya, Yuko and Tomiie, Yumi and Ogawa, Kimio and Kuki, Tomoki and Tanabe, Yosuke and Kato, Hisayuki and Imaizumi, Kazuyoshi and Hibi, Yatsuka and Kawada, Kenji},
  title = {A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  volume = {30},
  number = {11},
  pages = {2257--2265},
  doi = {10.1007/s10147-025-02861-8}
}
Kostenlos starten →